BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24158402)

  • 1. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
    Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
    Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
    Gerber DE; Grossman SA; Batchelor T; Ye X
    Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
    Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
    Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
    Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
    Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Škorić B; Kuzmanović M; Jovanović M; Miljković B; Micić D; Jović M; Jovanović A; Vučićević K
    Pediatr Hematol Oncol; 2023; 40(5):446-457. PubMed ID: 37195735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
    Xu W; Tang Y; Song H; Shi S; Yang S
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose methotrexate on plasma hypoxanthine and uridine levels in patients with acute leukemia or non-Hodgkin lymphoma in childhood.
    Hashimoto H; Kubota M; Shimizu T; Kasai Y; Sano H; Adachi S; Akiyama Y; Mikawa H
    Leukemia; 1992 Nov; 6(11):1199-202. PubMed ID: 1434805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.